Alzamend begins section 2 trial for lithium-based oral therapy for Alzheimer’s illness

Might 09, 2022

1 min learn

Alzamend Neuro Inc. has introduced the launch of a section 2A trial for its AL001 therapy for delicate to average Alzheimer’s dementia.

AL001 is being developed as an oral lithium-based remedy and has the potential to ship lithium carbonate to the mind whereas mitigating or avoiding present toxicities related to lithium.

Source: Adobe Stock.
Supply: Adobe Inventory.

“Advancing AL001 right into a section 2A scientific trial as deliberate marks an necessary milestone for Alzamend,” Alzamend CEO Stephan Jackman mentioned in a launched assertion. “We’re one step nearer to proving that AL001 might doubtlessly present clinicians with a significant enchancment over present lithium-based therapies and should represent a method of treating over 40 million Individuals affected by Alzheimer’s and different neurodegenerative illnesses and psychiatric issues.”

The primary affected person with delicate to average AD has obtained a dose of AL001 in a 12-month a number of ascending dose (MAD) examine, which is able to consider the security and tolerability of AL001 underneath multiple-dose, steady-state circumstances and decide the utmost tolerated dose in sufferers recognized with AD.

Based on the discharge, lithium has been well-characterized for security and is at the moment authorized in a number of formulations for the therapy of bipolar affective issues. Dosing for the MAD examine is predicated on a fraction of the everyday lithium dose utilized in these therapies.

“We look ahead to finishing the MAD examine and additional advancing scientific improvement of this promising potential therapeutic,” Jackman mentioned.


Leave a Reply